Showing 5191-5200 of 5956 results for "".
- BVI Expands Portfolio with New Viscoelastic; Forges Strategic Partnership with Cromahttps://modernod.com/news/bvi-expands-portfolio-with-new-viscoelastic-forges-strategic-partnership-with-croma/2477789/BVI announced it has acquired the ophthalmic viscoelastic device (OVD) assets from Austrian-based Croma. In addition to the acquisition of existing products, BVI and Croma have embarked on an R&D collaboration on additional products that will come to market. Terms of the deal were not
- Samsung Bioepis Announces 24-Week Interim Results From a Phase 3 Trial of Ranibizumab Biosimilarhttps://modernod.com/news/samsung-bioepis-announces-24-week-interim-results-from-a-phase-3-trial-of-ranibizumab-biosimilar/2477785/Samsung Bioepis announced that the primary endpoints have been met in the randomized, double-masked, phase 3 trial comparing the efficacy, safety and immunogenicity of SB11, a ranibizumab biosimilar candidate, to reference ranibizumab in patients with wet age-related macular degeneration (AMD).</
- Oculis Reports Topline Data From Phase 2 Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-reports-topline-data-from-phase-2-trial-with-ocs-01-for-treating-inflammation-and-pain-following-cataract-surgery/2477782/Oculis SA reported positive results from its phase 2 SKYGGN study of OCS-01, a novel, high concentration, preservative free, topical SNP formulation of dexamethasone (ophthalmic suspension 1.5%) for the treatment of inflammation and pain following cataract surgery. OCS-01 has been develope
- AMA Issues Guidance to Physicians on Using COVID-19 Antibody Testshttps://modernod.com/news/ama-issues-guidance-to-physicians-on-using-covid-19-antibody-tests/2477783/As new serology tests for COVID-19 rapidly come to the market, the American Medical Association (AMA) is cautioning physicians about using these tests to make healthcare decisions for individual patients, according to a FierceHealthcare
- MPR and MacuLogix Received A’Design Awardhttps://modernod.com/news/mpr-and-maculogix-received-adesign-award/2477781/MPR and MacuLogix were recognized with the A’Design Platinum Award, the world’s largest design competition, for its work on the AdaptDx Pro, a medical headset by MacuLogix. Launched earlier this year, the device build
- Prevent Blindness Unveils New Brand Identity, Logo and Websitehttps://modernod.com/news/prevent-blindness-unveils-new-brand-identity-logo-and-website/2477772/Prevent Blindness announced the launch of its new brand identity, logo, and website. The launch coincides with the organization’s new “Be a Visionary” campaign: a call to action to join in the sight-saving efforts of Prevent Blindness. The new identity is designed to refl
- Johnson & Johnson Vision Announces Global Initiatives to Support Eye Care Professionals and Patients During COVID-19 and Beyondhttps://modernod.com/news/johnson-johnson-vision-announces-global-initiatives-to-support-eye-care-professionals-and-patients-during-covid-19-and-beyond/2477770/Johnson & Johnson Vision is deploying solutions around the world to help address the challenges facing eye care professionals (ECPs) and their patients amid the COVID-19 pandemic. These support the broader efforts that Johnson & Johnson is taking to curb the crisis, including development
- ECPs Can Now Access Online Training to Certify to Prescribe CooperVision’s Brilliant Futures Myopia Management Programhttps://modernod.com/news/ecps-can-now-access-online-training-to-certify-to-prescribe-coopervisions-brilliant-futures-myopia-management-program/2477762/This month, CooperVision unveiled an online training curriculum so eye care professionals (ECPs) can certify to prescribe the Brilliant Futures Myopia Management Program featuring MiSight 1 day contact lenses. CooperVision will continue outreach to ECPs who have experience with pediatric populati
- The Vision Council Releases April COVID-19 Optical Impact Consumer Studyhttps://modernod.com/news/the-vision-council-releases-april-covid-19-optical-impact-consumer-study/2477763/The Vision Council has released the results of the April COVID-19 Optical Impact Consumer Study. The study, which launched in February and has continued since then as part of The Vision Council’s monthly VisionWatch consumer survey, gauges consumers’ level of concern about the COVID-19 pandemic a
- Ocular Therapeutix Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI For Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-1-clinical-trial-of-otx-csi-for-treatment-of-dry-eye-disease/2477754/Ocular Therapeutix announced that it has dosed the first patients in its phase 1 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED). “We are pleased to be advancing OTX-CSI in the chronic treatment of dry eye disease,” Michael Goldst